Aubagio FDA Approval History
FDA Approved: Yes (First approved September 12, 2012)
Brand name: Aubagio
Generic name: teriflunomide
Dosage form: Tablets
Treatment for: Multiple Sclerosis
Aubagio (teriflunomide) is an oral pyrimidine synthesis inhibitor indicated for the treatment of patients with relapsing forms of multiple sclerosis.
Development Timeline for Aubagio
|Sep 12, 2012||FDA Approves New Multiple Sclerosis Treatment Aubagio|
|Oct 20, 2011||Oral Therapy Teriflunomide (Aubagio) Significantly Reduces Relapses Leading to Hospitalization of Patients with Multiple Sclerosis|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.